Prestige Biologics Co., Ltd. (KOSDAQ:334970)

Revenue by Segment

Financials in millions KRW. Fiscal year is July - June.

Fiscal Year	FY 2024	FY 2023	FY 2021	FY 2019
Period Ending	Jun 30, 2024	Jun 30, 2023	Dec 31, 2021	Dec 31, 2019
Antibody Drugs	1.48B
Antibody Drugs Growth	-53.24%
Other than Service	689.62M
Other than Service Growth	132.37%

Revenue by Geography

Financials in millions KRW. Fiscal year is July - June.

Fiscal Year	FY 2024	FY 2023	FY 2021	FY 2019
Period Ending	Jun 30, 2024	Jun 30, 2023	Dec 31, 2021	Dec 31, 2019
South Korea	2.17B
South Korea Growth	-37.32%

Data Source: Finnhub Last updated: Mar 31, 2026

Financial data is provided by Finnhub and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 9, 2026

Data Sources Report a data error